BOLT BIOTHERAPEUTICS

Bolt Biotherapeutics to Present Updates for Three Preclinical Immuno-Oncology Pipeline Programs at AACR Annual Meeting 2022

08 Mar 2022 15:30:00 By Nasdaq GlobeNewswire

Bolt Biotherapeutics to Participate in Upcoming February Conferences

02 Feb 2022 07:00:01 By Nasdaq GlobeNewswire

Bolt Biotherapeutics Doses First Patient with BDC-1001 in Combination with OPDIVO® (nivolumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of HER2-Expressing Solid Tumors

06 Jan 2022 07:00:02 By Nasdaq GlobeNewswire

Bolt Biotherapeutics Appoints Nicole Onetto, M.D., to Board of Directors

16 Dec 2021 07:00:02 By Nasdaq GlobeNewswire

Bolt Biotherapeutics Reports Interim BDC-1001 Phase 1/2 Data Demonstrating a Safe and Well-tolerated Profile and Emerging Clinical Activity at the ESMO Immuno-Oncology Congress 2021

06 Dec 2021 05:00:00 By Nasdaq GlobeNewswire

Bolt Biotherapeutics to Present Interim Clinical Data on BDC-1001 Phase 1/2 Clinical Trial at ESMO Immuno-Oncology Congress 2021

02 Dec 2021 05:00:00 By Nasdaq GlobeNewswire

Bolt Biotherapeutics Announces Changes to its Board of Directors

19 Nov 2021 07:00:00 By Nasdaq GlobeNewswire

Bolt Biotherapeutics Presents New Preclinical Data on Three Pipeline Programs at Society for Immunotherapy of Cancer (SITC) Annual Meeting

12 Nov 2021 06:00:02 By Nasdaq GlobeNewswire

Bolt Biotherapeutics Reports Third Quarter 2021 Financial Results and Provides Business Highlights

09 Nov 2021 03:05:00 By Nasdaq GlobeNewswire

Bolt Biotherapeutics to Present at Stifel 2021 Virtual Healthcare Conference

08 Nov 2021 07:00:01 By Nasdaq GlobeNewswire

Bolt Biotherapeutics to Present Updates on Three Pipeline Programs at the 2021 Society for Immunotherapy of Cancer Annual Meeting (SITC)

01 Oct 2021 07:00:01 By Nasdaq GlobeNewswire

Bolt Biotherapeutics to Participate in Upcoming September Investor Conferences

02 Sep 2021 07:00:02 By Nasdaq GlobeNewswire

Bolt Biotherapeutics and Innovent Biologics Announce Collaboration to Develop Three New Oncology Boltbody™ ISAC Programs

26 Aug 2021 15:05:00 By Nasdaq GlobeNewswire

Bolt Biotherapeutics Reports Second Quarter 2021 Financial Results and Provides Business Highlights

12 Aug 2021 15:05:04 By Nasdaq GlobeNewswire

Bolt Biotherapeutics Presents Preliminary Results from Phase 1/2 Trial of Lead HER2-targeting Boltbody™ ISAC BDC-1001 at ASCO 2021

04 Jun 2021 08:00:00 By Nasdaq GlobeNewswire

Genmab and Bolt Biotherapeutics Announce Oncology Research and Development Collaboration

02 Jun 2021 07:00:02 By Nasdaq GlobeNewswire

Bolt Biotherapeutics Reports First Quarter 2021 Financial Results and Provides Business Highlights

13 May 2021 15:05:00 By Nasdaq GlobeNewswire

Bolt Biotherapeutics Announces AACR 2021 Presentation of Boltbody™ Platform Mechanism of Action and Clinical Properties of Lead ISAC, BDC-1001

10 Apr 2021 07:30:00 By Nasdaq GlobeNewswire

Bolt Biotherapeutics to Present at 20th Annual Needham Virtual Healthcare Conference

08 Apr 2021 06:00:00 By Nasdaq GlobeNewswire

Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights

31 Mar 2021 15:05:00 By Nasdaq GlobeNewswire